Titan Other Stockholder Equity vs Common Stock Shares Outstanding Analysis
| TTNP Stock | USD 6.51 0.15 2.36% |
Titan Pharmaceuticals financial indicator trend analysis is much more than just breaking down Titan Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Titan Pharmaceuticals is a good investment. Please check the relationship between Titan Pharmaceuticals Other Stockholder Equity and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
Other Stockholder Equity vs Common Stock Shares Outstanding
Other Stockholder Equity vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Titan Pharmaceuticals Other Stockholder Equity account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have strong relationship.
The correlation between Titan Pharmaceuticals' Other Stockholder Equity and Common Stock Shares Outstanding is 0.73. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Titan Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Titan Pharmaceuticals' Other Stockholder Equity and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Titan Pharmaceuticals are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Other Stockholder Equity i.e., Titan Pharmaceuticals' Other Stockholder Equity and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | 0.73 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Other Stockholder Equity
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Titan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.At this time, Titan Pharmaceuticals' Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 06/01/2024, Enterprise Value Over EBITDA is likely to grow to 0.0006, while Issuance Of Capital Stock is likely to drop slightly above 7.2 M.
Titan Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Titan Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Titan Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
| Short Long Term Debt Total | 4.4M | 809K | 299K | 187K | 565K | 536.8K | |
| Other Current Liab | 1.9M | 2.0M | 1.5M | 1.6M | 519K | 493.1K | |
| Total Current Liabilities | 3.6M | 4.2M | 2.7M | 2.6M | 1.4M | 1.4M | |
| Total Stockholder Equity | 1.4M | 3.5M | 5.1M | 1.4M | 6.6M | 6.3M | |
| Property Plant And Equipment Net | 1.2M | 759K | 717K | 407K | 68K | 64.6K | |
| Net Debt | (782K) | (4.6M) | (5.7M) | (2.8M) | (6.2M) | (6.5M) | |
| Retained Earnings | (349.0M) | (367.3M) | (376.1M) | (386.3M) | (391.8M) | (372.2M) | |
| Accounts Payable | 1.4M | 1.3M | 795K | 695K | 348K | 330.6K | |
| Cash | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 8.3M | |
| Non Current Assets Total | 1.2M | 759K | 765K | 455K | 68.0K | 64.6K | |
| Non Currrent Assets Other | 794K | (1.2M) | (759K) | 48K | (1.0) | (0.95) | |
| Cash And Short Term Investments | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 6.4M | |
| Net Receivables | 993K | 884K | 112K | 36K | 1.0M | 1.6M | |
| Common Stock Shares Outstanding | 1.3K | 188.7K | 486.5K | 671.7K | 752K | 789.6K | |
| Liabilities And Stockholders Equity | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
| Non Current Liabilities Total | 3.8M | 4.5M | 332K | 187K | 65K | 0.0 | |
| Other Stockholder Equity | 350.4M | 370.8M | 381.2M | 387.6M | 398.5M | 418.4M | |
| Total Liab | 8.1M | 4.6M | 2.9M | 2.7M | 1.4M | 1.4M | |
| Total Current Assets | 8.3M | 7.3M | 7.2M | 3.6M | 8.0M | 7.6M | |
| Short Term Debt | 272K | 477K | 112K | 122K | 565K | 1.1M | |
| Other Current Assets | 1.1M | 522K | 480K | 314K | 199K | 189.1K | |
| Property Plant And Equipment Gross | 1.2M | 618K | 2.1M | 2M | 774K | 883.3K | |
| Common Stock | 57K | 7K | 10K | 15K | 1K | 950.0 | |
| Property Plant Equipment | 794K | 1.2M | 759K | 717K | 824.6K | 826.4K | |
| Long Term Debt | 3.6M | 3.8M | 4.0M | 332K | 298.8K | 283.9K | |
| Retained Earnings Total Equity | (323.3M) | (332.6M) | (349.0M) | (367.3M) | (330.6M) | (347.1M) | |
| Net Tangible Assets | 6.8M | 1.4M | 3.5M | 5.1M | 4.6M | 4.7M | |
| Capital Surpluse | 26.3M | 339.4M | 350.4M | 370.8M | 426.4M | 447.7M | |
| Net Invested Capital | 5.5M | 4.2M | 5.1M | 1.4M | 7.1M | 4.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.42) | Revenue Per Share 0.245 | Quarterly Revenue Growth (1.00) | Return On Assets (0.75) | Return On Equity (1.39) |
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.